Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral therapy
non-nucleoside reverse transcriptase inhibitor |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AG06
|
| gptkbp:brand |
gptkb:Pifeltro
|
| gptkbp:CASNumber |
1338225-97-0
|
| gptkbp:combinationTherapy |
delstrigo
|
| gptkbp:combines |
gptkb:tenofovir_disoproxil_fumarate
gptkb:lamivudine |
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:eliminationHalfLife |
15 hours
|
| gptkbp:hasMolecularFormula |
C17H11ClF3N5O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
doravirine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 reverse transcriptase
|
| gptkbp:pregnancyCategory |
N/A (consult physician)
|
| gptkbp:proteinBinding |
76%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue headache |
| gptkbp:usedFor |
HIV-1 infection
|
| gptkbp:bfsParent |
gptkb:Delstrigo
gptkb:Pifeltro |
| gptkbp:bfsLayer |
6
|